MetaCap

Atea Pharmaceuticals (AVIR) vs Benitec Biopharma (BNTC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Atea Pharmaceuticals (AVIR) has outperformed Benitec Biopharma (BNTC) over the past year, gaining 33.3% versus a loss of 40.3%. Over five years, AVIR leads with a -51.4% price change compared with -85.7% for BNTC. Atea Pharmaceuticals is the larger company by market cap ($318.0 million vs $285.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AVIR+33.33%BNTC-40.31%
+114%+33%-48%
Nov 21, 20251 yearNov 20, 2026
AVIR-51.17%BNTC-85.45%
+18%-42%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AVIR versus BNTC key metrics
MetricAVIRBNTC
Share price$3.96$7.92
Market cap$318.00M$285.88M
1-day change+0.76%-2.76%
YTD return+10.92%-41.24%
1-year return+33.33%-40.31%
5-year return-51.35%-85.67%
EPS (TTM)$-1.95$-1.02
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-158.35M$-45.55M
52-week high$6.45$14.39
52-week low$2.96$7.72
Distance from 52-week high-38.60%-45.00%
Analyst consensusbuystrong_buy
Avg. price target upside+127.27%+200.06%
Average volume290.60K174.01K
Shares outstanding80.30M36.12M
Employees5524
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AVIR has outperformed BNTC by 73.6 percentage points over the past year.

About Atea Pharmaceuticals

AVIR stock →

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).

Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees

About Benitec Biopharma

BNTC stock →

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.

Health Care · Biotechnology: Pharmaceutical Preparations · 24 employees

AVIR vs BNTC FAQ

Which is bigger, Atea Pharmaceuticals or Benitec Biopharma?

Atea Pharmaceuticals (AVIR) is larger, with a market capitalization of $318.00M compared with $285.88M for Benitec Biopharma (BNTC).

Which stock has performed better over the past year, AVIR or BNTC?

AVIR returned +33.33% over the past 12 months, compared with -40.31% for BNTC (price return, excluding dividends). Past performance does not predict future results.

Are Atea Pharmaceuticals and Benitec Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons